2025 Result of Annual General Meeting
12th June 2025 - 1:26 pmImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 – 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details are contained in the table below.
| Resolution | For | % For | Against | % Against | Withheld |
| 1. To receive the accounts of the Company for the year ended 31 December 2024 together with the reports thereon of the directors and auditors of the Company | 88,682,323 | 74 | 30,840,722 | 26 | 74,472 |
| 2. To re-appoint Dr Tim Franklin as a director of the Company | 86,938,536 | 74 | 31,136,460 | 26 | 1,522,521 |
| 3. To re-appoint Tim McCarthy as a director of the Company | 86,900,286 | 73 | 32,579,135 | 27 | 118,096 |
| 4. To re-appoint Crowe UK LLP as Auditor of the Company | 86,901,988 | 76 | 27,981,718 | 24 | 4,713,811 |
| 5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the “Act”) to allot shares on the basis as set out in the Notice of Meeting | 84,856,858 | 71 | 34,558,813 | 29 | 181,846 |
| SPECIAL RESOLUTION 6. That, subject to the passing of Resolution 5 the directors be and they are hereby empowered pursuant to section 571 of the Act to allot equity securities as set out in the Notice of Meeting | 84,812,828 | 71 | 34,602,843 | 29 | 181,846 |
To download announcement click here